These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27320920)

  • 1. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
    Carugo A; Genovese G; Seth S; Nezi L; Rose JL; Bossi D; Cicalese A; Shah PK; Viale A; Pettazzoni PF; Akdemir KC; Bristow CA; Robinson FS; Tepper J; Sanchez N; Gupta S; Estecio MR; Giuliani V; Dellino GI; Riva L; Yao W; Di Francesco ME; Green T; D'Alesio C; Corti D; Kang Y; Jones P; Wang H; Fleming JB; Maitra A; Pelicci PG; Chin L; DePinho RA; Lanfrancone L; Heffernan TP; Draetta GF
    Cell Rep; 2016 Jun; 16(1):133-147. PubMed ID: 27320920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
    Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
    Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
    Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
    Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
    Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
    Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
    Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
    Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma.
    Wong CH; Li CH; He Q; Chan SL; Tong JH; To KF; Lin LZ; Chen Y
    Cancer Lett; 2020 May; 477():1-9. PubMed ID: 32120024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
    Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
    Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2.
    Vogt M; Dudvarski Stankovic N; Cruz Garcia Y; Hofstetter J; Schneider K; Kuybu F; Hauck T; Adhikari B; Hamann A; Rocca Y; Grysczyk L; Martin B; Gebhardt-Wolf A; Wiegering A; Diefenbacher M; Gasteiger G; Knapp S; Saur D; Eilers M; Rosenfeldt M; Erhard F; Vos SM; Wolf E
    Gut; 2024 Aug; 73(9):1509-1528. PubMed ID: 38821858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription.
    Peng WX; He RZ; Zhang Z; Yang L; Mo YY
    Oncogene; 2019 Oct; 38(41):6770-6780. PubMed ID: 31391552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
    Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
    Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
    Giuliani V; Miller MA; Liu CY; Hartono SR; Class CA; Bristow CA; Suzuki E; Sanz LA; Gao G; Gay JP; Feng N; Rose JL; Tomihara H; Daniele JR; Peoples MD; Bardenhagen JP; Geck Do MK; Chang QE; Vangamudi B; Vellano C; Ying H; Deem AK; Do KA; Genovese G; Marszalek JR; Kovacs JJ; Kim M; Fleming JB; Guccione E; Viale A; Maitra A; Emilia Di Francesco M; Yap TA; Jones P; Draetta G; Carugo A; Chedin F; Heffernan TP
    Nat Commun; 2021 Jul; 12(1):4626. PubMed ID: 34330913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
    Neilsen BK; Chakraborty B; McCall JL; Frodyma DE; Sleightholm RL; Fisher KW; Lewis RE
    BMC Cancer; 2018 Jun; 18(1):673. PubMed ID: 29925347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
    Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
    Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
    Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
    J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.
    Schneider G; Saur D
    Trends Cancer; 2016 Aug; 2(8):391-392. PubMed ID: 28741490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.
    Kashiwaya K; Nakagawa H; Hosokawa M; Mochizuki Y; Ueda K; Piao L; Chung S; Hamamoto R; Eguchi H; Ohigashi H; Ishikawa O; Janke C; Shinomura Y; Nakamura Y
    Cancer Res; 2010 May; 70(10):4024-33. PubMed ID: 20442285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.